In conclusion, we described that serum Gal-9 levels were associated with RP-ILD and disease activity in anti-MDA5-positive patients with DM, and Gal-9 upregulated CCL2 mRNA levels in MRC-5 fibroblasts in vitro. This evidence concerns the gene CCL2 and dermatomyositis.